[go: up one dir, main page]

GT200800201A - Derivados de estirilpiridina y sus usos para union a placas amiloides y obtención de imagenes de las mismas. - Google Patents

Derivados de estirilpiridina y sus usos para union a placas amiloides y obtención de imagenes de las mismas.

Info

Publication number
GT200800201A
GT200800201A GT200800201A GT200800201A GT200800201A GT 200800201 A GT200800201 A GT 200800201A GT 200800201 A GT200800201 A GT 200800201A GT 200800201 A GT200800201 A GT 200800201A GT 200800201 A GT200800201 A GT 200800201A
Authority
GT
Guatemala
Prior art keywords
amiloid
obtaining images
stirilpiridina
joining
derivatives
Prior art date
Application number
GT200800201A
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800201A publication Critical patent/GT200800201A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCIÓN SE RELACIONA CON UN MÉTODO PARA OBTENER IMÁGENES DE DEPÓSITOS AMILOIDES Y CON COMPUESTOS DE ESTIRILPIRIDINA, Y MÉTODOS PARA PREPARAR COMPUESTOS RADIOMARCADOS DE ESTIRILPIRIDINA ÚTILES PARA OBTENER IMÁGENES DE DEPÓSITOS AMILOIDES. ESTA INVENCIÓN TAMBIÉN SE RELACIONA CON COMPUESTOS Y MÉTODOS PARA PREPARAR COMPUESTOS PARA INHIBIR LA AGREGACIÓN DE PROTEÍNAS AMILOIDES QUE FORMA LOS DEPÓSITOS AMILOIDES, Y UN MÉTODO PARA ADMINISTRAR UN AGENTE TERAPÉUTICO A LOS DEPÓSITOS AMILOIDES. T2008
GT200800201A 2006-03-30 2008-09-30 Derivados de estirilpiridina y sus usos para union a placas amiloides y obtención de imagenes de las mismas. GT200800201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
GT200800201A true GT200800201A (es) 2009-08-20

Family

ID=38326579

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800201A GT200800201A (es) 2006-03-30 2008-09-30 Derivados de estirilpiridina y sus usos para union a placas amiloides y obtención de imagenes de las mismas.

Country Status (34)

Country Link
US (3) US7687052B2 (es)
EP (3) EP2363392B1 (es)
JP (1) JP5290954B2 (es)
KR (1) KR101376807B1 (es)
CN (1) CN101522624B (es)
AT (1) ATE539060T1 (es)
AU (1) AU2007243712B2 (es)
BR (1) BRPI0710225B1 (es)
CA (1) CA2644530C (es)
CR (1) CR10329A (es)
CY (3) CY1113048T1 (es)
DK (2) DK1999109T3 (es)
EA (1) EA017898B1 (es)
EC (1) ECSP088783A (es)
ES (2) ES2628882T3 (es)
FR (1) FR13C0034I2 (es)
GT (1) GT200800201A (es)
HR (2) HRP20120135T1 (es)
HU (2) HUE032660T2 (es)
IL (1) IL193567A (es)
LT (1) LT2363392T (es)
LU (1) LU92232I2 (es)
MX (1) MX2008012527A (es)
NO (2) NO342090B1 (es)
NZ (1) NZ570887A (es)
PL (2) PL2363392T3 (es)
PT (2) PT1999109E (es)
RS (2) RS52222B (es)
SG (1) SG173338A1 (es)
SI (2) SI1999109T1 (es)
TW (1) TWI399366B (es)
UA (1) UA97802C2 (es)
WO (1) WO2007126733A2 (es)
ZA (1) ZA200807955B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5290954B2 (ja) * 2006-03-30 2013-09-18 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用
WO2009004914A1 (ja) * 2007-07-04 2009-01-08 Tohoku University フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
JP5603855B2 (ja) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
NZ593848A (en) * 2008-12-31 2013-09-27 Avid Radiopharmaceuticals Inc Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
CN102471177A (zh) * 2009-07-10 2012-05-23 拜耳医药股份有限公司 低至中压液相色谱在放射性示踪剂纯化中的应用
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US20120328521A1 (en) * 2009-12-23 2012-12-27 Piramal Imaging Sa Formulations suitable for pet imaging with hydrophobic pet agents
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
EA025823B1 (ru) 2010-06-04 2017-02-28 Пирамаль Имэджинг Са Способ получения f-18 меченых лигандов бета-амилоида
AU2011260419A1 (en) * 2010-06-04 2012-12-20 Piramal Imaging Sa Method for production of F-18 labeled amyloid beta ligands
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
EP2579902B2 (en) 2010-06-04 2019-08-14 Piramal Imaging SA Method for production of f-18 labeled amyloid beta ligands
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
EP3263136A1 (en) * 2010-10-12 2018-01-03 Mayo Foundation for Medical Education and Research Imaging of meningiomas using stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
AU2012245861A1 (en) 2011-04-21 2013-10-17 The Regents Of The University Of California Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles
CA2852840A1 (en) 2011-10-19 2013-04-25 Piramal Imaging Sa Improved method for production of f-18 labeled a.beta. ligands
KR101930124B1 (ko) 2012-04-10 2018-12-17 랜티우스 메디컬 이메징, 인크. 방사성제약 합성 방법
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
KR102618139B1 (ko) 2014-05-13 2023-12-27 에프. 호프만-라 로슈 아게 중수소화된 헤테로사이클릭 화합물 및 이의 조영제로서의 용도
EP3337475B1 (en) * 2015-08-18 2024-10-02 The Regents of The University of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
EP4619384A1 (en) 2022-11-14 2025-09-24 Eli Lilly and Company Polymorphic forms of florbetapir precursor av-105

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
EP1432453B1 (en) * 2001-08-27 2013-08-14 The Trustees of The University of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
MXPA04012068A (es) 2002-06-06 2005-03-07 Univ Pennsylvania Anodos de ceramica y metodos de produccion de los mismos.
AU2003258612A1 (en) * 2002-08-14 2004-03-03 4Sc Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
WO2006078384A2 (en) * 2004-12-17 2006-07-27 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use
SI2213652T1 (sl) * 2004-12-17 2015-03-31 The Trustees Of The University Of Pennsylvania Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
CA2617319A1 (en) * 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
JP5290954B2 (ja) * 2006-03-30 2013-09-18 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用
US20080253967A1 (en) 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
US20130129624A1 (en) 2013-05-23
CA2644530C (en) 2015-05-19
US20090123369A1 (en) 2009-05-14
DK1999109T3 (da) 2012-04-02
AU2007243712A1 (en) 2007-11-08
SI1999109T1 (sl) 2012-04-30
NO342090B1 (no) 2018-03-19
US8840866B2 (en) 2014-09-23
EP2363391A1 (en) 2011-09-07
LT2363392T (lt) 2017-07-25
ECSP088783A (es) 2008-10-31
UA97802C2 (uk) 2012-03-26
CN101522624A (zh) 2009-09-02
WO2007126733A3 (en) 2008-03-06
AU2007243712B2 (en) 2013-01-10
DK2363392T3 (en) 2017-07-03
PT1999109E (pt) 2012-03-16
TW200838852A (en) 2008-10-01
RS56171B1 (sr) 2017-11-30
LU92232I2 (fr) 2013-08-26
MX2008012527A (es) 2008-10-14
JP5290954B2 (ja) 2013-09-18
ES2378785T3 (es) 2012-04-17
NO20084590L (no) 2008-12-29
EP2363392B1 (en) 2017-05-03
TWI399366B (zh) 2013-06-21
HUE032660T2 (en) 2017-10-30
RS52222B (sr) 2012-10-31
CY1119048T1 (el) 2018-01-10
KR20080106564A (ko) 2008-12-08
FR13C0034I2 (fr) 2014-03-07
JP2009532349A (ja) 2009-09-10
NZ570887A (en) 2011-05-27
EP2363392A1 (en) 2011-09-07
US20080038195A1 (en) 2008-02-14
BRPI0710225A2 (pt) 2011-08-02
HRP20170857T1 (hr) 2017-12-01
CY1113048T1 (el) 2015-11-04
EP1999109A2 (en) 2008-12-10
HUS1300028I1 (hu) 2017-08-28
WO2007126733A2 (en) 2007-11-08
NO2018030I1 (no) 2018-09-11
FR13C0034I1 (es) 2013-08-09
EP1999109B1 (en) 2011-12-28
IL193567A0 (en) 2009-05-04
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
KR101376807B1 (ko) 2014-03-20
IL193567A (en) 2014-03-31
ATE539060T1 (de) 2012-01-15
EA017898B1 (ru) 2013-04-30
CY2013024I2 (el) 2015-11-04
ES2628882T3 (es) 2017-08-04
CY2013024I1 (el) 2015-11-04
LU92232I9 (es) 2019-01-15
BRPI0710225B1 (pt) 2021-07-13
US7687052B2 (en) 2010-03-30
CR10329A (es) 2008-10-29
HRP20120135T1 (hr) 2012-03-31
SG173338A1 (en) 2011-08-29
PL2363392T3 (pl) 2017-10-31
CN101522624B (zh) 2013-11-06
US8506929B2 (en) 2013-08-13
SI2363392T1 (sl) 2017-09-29
ZA200807955B (en) 2012-11-28
EA200870389A1 (ru) 2009-04-28
CA2644530A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
GT200800201A (es) Derivados de estirilpiridina y sus usos para union a placas amiloides y obtención de imagenes de las mismas.
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
SV2009003289A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico para imagenes
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CR20140313A (es) Compuestos de biaril éter urea
ECSP099785A (es) Anticuerpos anti-notch1 nrr y sus métodos de uso
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
CR10987A (es) Composiciones dispersables en agua y los metodos para utilizar las composiciones dispersables en agua
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
PA8807601A1 (es) Moleculas de union al receptor ox40 humano
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
UY34870A (es) Cristales de sal
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
UY30409A1 (es) Pirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
BR112016006951A2 (pt) novas vias de síntese para prostaglandinas e intermediários de prostaglandina com o uso de metátese
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
UY32112A (es) Compuestos que se unen a las placas amiloides para obtener imágenes de las mismas y su uso
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
GT200500382A (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso